Pfizer, Buying 12-Percent Stake in Perlegen and Penning Research Alliance, Bolsters PGx Play | GenomeWeb

Add Pfizer to the short list of Perlegen owners. The world's largest drug maker by revenue last week disclosed that it bought a 12-percent stake in the Mountain View, Calif.-based pharmacogenomics company, and has promised to invest more if Perlegen goes public.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.